2,850,769 Shares in Geron Corporation $GERN Acquired by Nuveen LLC

Nuveen LLC bought a new position in shares of Geron Corporation (NASDAQ:GERN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,850,769 shares of the biopharmaceutical company’s stock, valued at approximately $4,533,000. Nuveen LLC owned approximately 0.45% of Geron as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in Geron during the 4th quarter worth approximately $36,000. Sowell Financial Services LLC bought a new position in shares of Geron during the 1st quarter worth approximately $43,000. GF Fund Management CO. LTD. bought a new position in shares of Geron during the 4th quarter worth approximately $45,000. 111 Capital bought a new position in shares of Geron during the 4th quarter worth approximately $52,000. Finally, Fifth Lane Capital LP bought a new position in shares of Geron during the 4th quarter worth approximately $53,000. 73.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GERN has been the subject of several research reports. The Goldman Sachs Group initiated coverage on shares of Geron in a research note on Thursday, July 10th. They set a “sell” rating and a $1.00 price target for the company. Scotiabank cut shares of Geron from a “sector outperform” rating to a “sector perform” rating and decreased their price target for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.19.

Geron Price Performance

NASDAQ:GERN opened at $1.46 on Wednesday. Geron Corporation has a 1-year low of $1.09 and a 1-year high of $4.83. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $1.54. The stock has a market capitalization of $931.51 million, a PE ratio of -11.23 and a beta of 0.73.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The business had revenue of $49.04 million during the quarter, compared to the consensus estimate of $47.30 million. During the same quarter last year, the firm posted ($0.10) EPS. The company’s quarterly revenue was up 5455.6% on a year-over-year basis. On average, research analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.